Showing 2391-2400 of 7606 results for "".
Understanding the Legalities of Off-label Use
https://practicaldermatology.com/topics/practice-management/understanding-the-legalities-of-off-label-use/20317/Off-label use is part and parcel of dermatology practice, but confusion about the practice persists. Here's what you should know.To Sell or Not To Sell: Strategic Options and Realizing Value
https://practicaldermatology.com/topics/practice-management/to-sell-or-not-to-sell-strategic-options-and-realizing-value/20418/Is this the right time to make a change? Here's what you need to know.Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execValeant's Plan for Derm; VCS Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-valeant-s-plan-for-derm-vcs-highlights/18587/Amid reports that its Obagi and Solta units may be sold off, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Vegas Cosmetic Surgery has wrapped up its 12th program, gathering dermatologists, plastic surgeons, facial pBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentFDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.Financial Benchmarking Update for Dermatology Practices
https://practicaldermatology.com/topics/practice-management/financial-benchmarking-update-for-dermatology-practices/22939/Successful practices use benchmarking to compare their performance to others, assess their own performance over time, and plan for the long-term.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Evaluating GEP Test Options
https://practicaldermatology.com/programs/practical-dermatology/evaluating-gep-test-options/35600/David Cotter, MD, a board-certified dermatologist, discusses what he looks for in a gene expression profile (GEP) test, including the types of clinical evidence that are most important.From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, F